Shares of Candel Therapeutics (NASDAQ:CADL) fell 20% Tuesday after the company reported final overall survival data from a Phase 2 study of its drug CAN-2409 in the treatment of pancreatic cancer.

The study evaluated CAN-2409 in combination with valacyclovir along